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Abstract: Short chain fatty acids (SCFAs) are generated by the degradation and fermentation
of complex carbohydrates, (i.e., dietary fiber) by the gut microbiota relevant for microbe–host
communication. Here, we present a method for the quantification of SCFAs in fecal samples
by liquid chromatography tandem mass spectrometry (LC-MS/MS) upon derivatization to
3-nitrophenylhydrazones (3NPH). The method includes acetate, propionate, butyrate, and isobutyrate
with a run time of 4 min. The reproducible (coefficients of variation (CV) below 10%) quantification
of SCFAs in human fecal samples was achieved by the application of stable isotope labelled internal
standards. The specificity was demonstrated by the introduction of a quantifier and qualifier
ions. The method was applied to investigate the pre-analytic stability of SCFAs in human feces.
Concentrations of SCFA may change substantially within hours; the degree and kinetics of these
changes revealed huge differences between the donors. The fecal SCFA level could be preserved
by the addition of organic solvents like isopropanol. An analysis of the colon content of mice
either treated with antibiotics or fed with a diet containing a non-degradable and -fermentable fiber
source showed decreased SCFA concentrations. In summary, this fast and reproducible method
for the quantification of SCFA in fecal samples provides a valuable tool for both basic research and
large-scale studies.
Keywords: SCFA; mass spectrometry; feces; LC-MS/MS; method validation
1. Introduction
Short-chain fatty acids (SCFAs) acetate (FA 2:0; annotation according to [1]), propionate (FA 3:0),
and butyrate (FA 4:0) are generated as end products, by the degradation and fermentation of
indigestible carbohydrates by the gut microbiota, a process termed saccharolytic fermentation [2].
SCFAs reach circulation via the portal vein and can then alter the host metabolism and physiology
substantially. They can act as signaling molecules as ligands of G-protein-coupled receptors [3].
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Physiologically, SCFAs are implicated in the increase of anorexic hormone production and energy
expenditure [3]. Consequently, SCFA production was linked to preventing the progression of
obesity and related complications, such as type 2 diabetes mellitus and nonalcoholic fatty liver
disease (NAFLD) [3,4]. Related to these functions, we have just recently identified in mice that gut
microbiota-derived acetate is an important precursor for the synthesis of fatty acids and phospholipids
in the liver [5].
Branched chain fatty acids (BCFA) like isobutyrate (FA 3:0(2Me)), 2-methylbutyrate (FA 4:0(2Me)),
and isovalerate (FA 4:0(3Me)) are derived from the fermentation of branched-chain amino acids
(BCAAs) [6]. In contrast to straight chain SCFA, these compounds are considered detrimental to
colonic and metabolic health [4].
SCFAs are typically quantified by gas chromatography (GC), liquid chromatography (LC),
nuclear magnetic resonance (NMR), and capillary electrophoresis (CE) (recently reviewed in the
literature [7]). In the last years, LC coupled to tandem mass spectrometry (LC-MS/MS) was
increasingly applied to quantify SCFA. These methods require derivatization using, for example,
2-nitrophenylhydrazin [8], 3-nitrophenylhydrazine [9], O-benzylhydroxylamine [10], or aniline [11].
Here, we present a novel LC-MS/MS method for the quantification of major SCFAs in fecal
samples, based on 3-nitrophenylhydrazone (3NPH) derivatization. The fast and reproducible method
was applied to investigate the pre-analytic stability of SCFA in human feces. Furthermore, the colon
contents were analyzed from mice treated with antibiotics to eliminate microbial SCFA producers, or
fed a diet containing solely a non-degradable and -fermentable fiber source (i.e., cellulose).
2. Materials and Methods
2.1. Reagents
Formic acid of analytical grade, acetonitrile, and isopropanol LiChrosolv were purchased
from Merck (Darmstadt, Germany). Acetic, propionic, butyric and isobutyric acid, pyridine,
N,N-dimethylglycine (DMG), and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide (EDC) were
purchased from Sigma Aldrich Chemie GmbH (Steinheim, Germany). The methanol LC-MS
Chromasolv was purchased from Honeywell Riedel-de Haën (Seelze, Germany). [13C,D3]-acetic
acid, [D5]-propionic acid, and [D7]-butyric acid were from Cambridge Isotope Laboratories
(Tewksbury, MA, USA). Stock solutions of the SCFAs, including the labeled compounds, were prepared
in water and were stored at −80 ◦C.
2.2. Preparation of Human Fecal and Murine Colon Content Homogenates
The human fecal samples for the method development were obtained from healthy volunteers
and were homogenized as described previously [12]. In brief, the fecal samples were homogenized in a
gentleMACS™ Dissociator (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) in 70%-isopropanol.
The dry weight (DW) was determined by the overnight drying of an aliquot in a vacuum centrifuge.
The feces homogenates were diluted to a concentration of 2.0 mg DW/mL. The samples were stored at
−80 ◦C and were kept on ice during processing. For the SCFAs, an aliquot of the homogenate was
centrifuged and the clear supernatant was subjected to derivatization.
The colon content from the mice were homogenized by bead beating (1.4 mm ceramic beads)
using a Precellys homogenizer (Bertin Technologies, Montigny Le Bretonneux, France). The samples
(10 to 30 mg weight) were homogenized in 1 mL 70%-isopropanol twice with 15 s agitation and 60 s
break. Then, 300 µL of the homogenate was used to determine the DW. The dilution and further
handling were identical as that described for the human samples.
2.3. Sample Preparation
Clear supernatants of the fecal and colon samples were subjected to 3-nitrophenylhydrazone
(3NPH) derivatization according to the method described by Han et al. [9], with some modifications.
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In brief, 50 µL of an aqueous internal standard mixture containing 100 µg/mL each of [13C,D3]-acetic
acid and [D5]-propionic acid, and 500 µg/mL of [D7]-butyric acid were added to 50 µL supernatant
of feces homogenate (2 mg DW/mL) and mixed. Then, 20 µL of 200 mM 3-nitrophenylhydrazine
hydrochloride and 20 µL of 120 mM N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride
were added and mixed for 30 min at 40 ◦C. The reaction was quenched by the addition of 200 µL of
0.1% formic acid and were used for the LC-MS/MS analysis.
2.4. Calibrators and Quality Controls
Pooled human fecal homogenates were used to prepare the matrix calibrators [12]. For low levels
(level II and III), this pool was diluted with 70%-isopropanol. High levels (level V and VI) were
generated by the supplementation of SCFA from concentrated aqueous solutions. The calibration lines
contained six levels in the concentration range, shown in Figure S1A–D.
The samples from three individuals with low, medium, and high SCFAs were aliquoted and used
as the quality control samples and for the method validation (see Section 3.4).
2.5. LC-MS/MS
SCFAs quantification was performed by liquid chromatography-tandem mass spectrometry
(LC-MS/MS). A 1200 series binary pump, isocratic pump, and degasser (Agilent, Waldbronn, Germany)
with an HTC Pal autosampler (CTC Analytics, Zwingen, Switzerland) was coupled to a hybrid triple
quadrupole linear ion trap mass spectrometer API 4000 Q-Trap equipped with a Turbo V source ion
spray (Applied Biosystems, Darmstadt, Germany).
The SCFAs were separated using a Kinetex®2.6 µm XB-C18, 50 × 2.1 mm (Phenomenex, Torrance,
CA, USA), with water as mobile phase A and acetonitrile as mobile phase B, both containing 0.1%
formic acid. The gradient elution started with 10% B, with a linear increase to 20% B at 0.3 min,
followed by an increase to 23% B at 2.5 min. The column was cleaned with 100% B from 2.6 to 3.0 min,
and was re-equilibrated from 3.1 to 4 min with 90% A. The column flow was 500 µL at 60 ◦C and 2 µL
of the sample were injected. To minimize the contamination of the mass spectrometer, the column
flow was only directed from 55 to 160 s into the mass spectrometer, using a diverter valve. Otherwise,
methanol with a flow rate of 250 µL/min was delivered into the mass spectrometer.
The Turbo Ion Spray source was operated in the negative ionization mode, using the following
settings: ion spray voltage = −4500 V, ion source heater temperature = 450 ◦C, source gas 1 = 55 psi,
source gas 2 = 50 psi, and curtain gas setting = 25 psi. The analytes were monitored in the multiple
reaction monitoring (MRM) mode, and the mass transitions and MS parameters are shown in Table 1.
Quadrupoles Q1 and Q3 were operated at unit resolution.
Table 1. LC-MS/MS of the short chain fatty acid (SCFA)–3-nitrophenylhydrazones (3NPH) derivatives.
Displayed are the retention time (RT), mass transitions (quantifier and qualifier ions) of analytes and
stable isotope labelled internal standards, declustering potential (DP), and collision energy (CE), as
well as the limit of detection (LoD) and highest calibration level for the LC-MS/MS quantification of
SCFA–3NPH derivatives.
Analyt RT(min)
Quantifier
(m/z)
Qualifier
(m/z)
DP
(V)
CE
(V)
LoD
(µmol/g
DW)
Highest
Calibrator
(µmol/g DW)
FA 2:0 1.18 194.1 > 151.1 194.1 > 137.1 −50 −17 1.9 1020
[13C,D3]-FA 2:0 1.17 198.1 > 153.1 198.1 > 137.1 −50 −17 - -
FA 3:0 1.63 208.1 > 165.1 208.1 > 137.1 −60 −20 0.2 446
[D5]-FA 3:0 1.61 213.1 > 170.1 213.1 > 137.1 −60 −20 - -
FA 4:0 2.53 222.1 > 179.1 222.1 > 137.1 −60 −20 0.06 440
FA 3:0 (2Me) 2.36 222.1 > 179.1 222.1 > 137.1 −60 −20 0.03 235
[D7]-FA 4:0 2.47 229.1 > 185.1 229.1 > 137.1 −60 −20 - -
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2.6. Method Validation
The method validation was performed on the basis of the FDA [13] and EMA [14] guidelines on
bioanalytical method validation.
The limit of the limit of detection (LoD) was determined by calculation of the signal to noise (S/N)
ratios, as the concentration with S/N = 3 for the analytes devoid of chemical background. For SCFAs
with a chemical background in the blank samples, the LoD was calculated from a limit of blank (LoB)
and a variation of a sample with a low concentration, as described previously [15] (Supplementary
Table S1), as follows:
LoB = mean(blank) + 1.645 SD(blank) (1)
LoD = LoB + 1.645 SD(low concentration sample) (2)
2.7. Investigation of Pre-Analytic Stability
Three healthy volunteers collected fresh stool samples and transported them to the laboratory
on ice. The samples were homogenized in water using a gentleMACS™ Dissociator, as described
above. The fecal homogenates were aliquoted and diluted with the same volume of water, methanol,
or isopropanol, to receive 70% organic solutions for alcohol containing homogenates. The aliquots of
these homogenates were frozen either immediately at −80 ◦C, or were stored for 0.5, 1, 3, 6, 24, 72,
and 168 h at room temperature or 4 ◦C before freezing.
2.8. Mouse Experiments
Specific pathogen free (SPF) C57BL/6 N mice were housed at 22 ± 1 ◦C and 50%–60% relative
humidity, with a 12 h light–dark cycle as described previously in detail [5]. The mice were fed a chow
diet (autoclaved, V1534, ssniff Spezialdiäten GmbH, Soest, Germany) ad libitum. For the antibiotic
treatment, sole mice were fed a chow mash containing vancomycin (0.25 g/L) and metronidazol
(1 g/L) (Sigma Aldrich, Steinheim, Germany) ad libitum for two days at the age of eight weeks,
without any additional food (per group: male/female, 1/1). The control group received the same diet
supplemented with water. The mouse experiment was performed according to the relevant ethical
guidelines. The breeding and experimental use of the mice in the facilities at the Technische Universität
München (School of Life Sciences Weihenstephan) was approved by the local institution in charge
(Regierung von Oberbayern; approval number 55.2-1-54-2531-99-13 and 55.2-1-54-2532-17-2015).
For dietary intervention, the C57BL/6 N mice at the age of six weeks were fed for two weeks
either a standard chow diet (5% grain–soybean-based crude fiber extract; V1534, ssniff) or a purified
control diet with a comparable carbohydrate, fat, and protein content as chow, but with purified
cellulose (5%) as the sole fiber source (autoclaved, S5745-E702, ssniff).
2.9. Statistical Analyses
IBM SPSS Statistics 25 was used for the statistical testing. The mouse experiments were analyzed
using a non-parametric Mann–Whitney U test.
3. Results
3.1. Sample Preparation and Chromatography
The aim of the current study was to develop an accurate, robust, and fast method for
the quantification of SCFA (up to four C-atoms) in fecal samples by LC-MS/MS. The SCFAs
were determined in an aliquot representing 100 µg DW. The derivatization of SCFAs to
3-nitrophenylhydrazones (3NPH) was performed according to the protocol described by Han et al. [9].
The derivatization reaction was stopped by the addition of formic acid. For accurate quantification,
stable isotope labeled SCFAs were added to the derivatization as internal standards (ISs) for each
straight chain SCFA (i.e., [13C,D3]-FA 2:0, [D5]-FA 3:0, [D7]-FA 4:0).
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The chromatographic separation of SCFA–3NPHs was optimized in order to achieve the fast
separation of isomeric butyric acid FA 4:0 and iso-butyric acid FA 3:0(2Me). A water–acetonitrile
gradient was applied on a C18 core shell material. FA 4:0 and FA 3:0(2Me) eluted at 2.36 and 2.53 min
showed an acceptable separation with a peak resolution R ≈ 1.4 (Figure 1), respectively. Including
column cleaning and re-equilibration, the method has a run time of 4 min.Bio olecules 2019, 9, x 5 of 13 
 
Figure 1. Chromatogram of short chain fatty acids (SCFAs) and their internal standards. Displayed 
are the extracted ion chromatograms of SCFAs, and their internal standards of a representative 
human fecal sample. 
3.2. Specificity and Matrix Effects 
Here, we applied, in addition to the fragment ion m/z 137 resulting from the 3NPH-moiety of 
the derivatives, a fragment specific for the respective SCFAs generated most likely from a neutral 
loss of isocyanic acid (Table 1; Supplementary Figure S1A–D for the product ion spectra). As a result 
of their lower background level, neutral loss fragment ions were used as quantifier. The calculation 
of the quantifier/qualifier ion ratios permits the evaluation of specificity for individual samples. The 
quantifier/qualifier ratios calculated for a batch with more than 100 different human fecal samples 
(data not included here) showed the following variations: FA 2:0 ratio 2.31 (3.4% coefficients of 
variation (CV), range 91% to 108% of the mean), FA 3:0 ratio 1.02 (2.8% CV, range 95% to 115% of the 
mean), FA 4:0 ratio 0.59 (5.5% CV, range 97% to 110% of mean), and FA 3:0(2Me) ratio 0.40 (4.4% CV, 
range 81% to 113% of the mean). Moreover, the mean of these ratios closely resembles those of the 
authentic standards and calibrators. For the same study, the variation of the intensities of the 
internal standards were calculated as a surrogate for the matrix effects, as follows: [13C, D3]-FA 2:0 
(6.2% CV, range 85% to 118% of the mean), [D5]-FA 3:0 (5.6% CV, range 82% to 113% of the mean), 
and [D7]-FA 4:0 (3.0% CV, range 92% to 107% of the mean). In addition to the low variation in the IS 
intensities between the different samples, the intensities observed in the fecal samples were 
comparable to those in the IS blanks and low calibrator levels with diluted sample matrix samples 
(data not shown). 
Table 1. LC-MS/MS of the short chain fatty acid (SCFA)–3-nitrophenylhydrazones (3NPH) 
derivatives. Displayed are the retention time (RT), mass transitions (quantifier and qualifier ions) of 
analytes and stable isotope labelled internal standards, declustering potential (DP), and collision 
energy (CE), as well as the limit of detection (LoD) and highest calibration level for the LC-MS/MS 
quantification of SCFA–3NPH derivatives. 
Analyt 
RT 
(min) 
Quantifier (m/z) Qualifier (m/z) 
DP 
(V) 
CE 
(V) 
LoD 
(µmol/g DW) 
Highest Calibrator 
(µmol/g DW) 
FA 2:0 1.18 194.1 > 151.1 194.1 > 137.1 −50 −17 1.9 1020 
Figure 1. Chromatogram of short chain fatty acids (SCFAs) and their inter al standards. Di played r
the xtracted ion chr matograms of SCFAs, and their internal stand rds of a epresentative human
fecal s mple.
3.2. Specificity and Matrix Effects
Here, we applied, in addition to the fragment ion m/z 137 resulting from the 3NPH-moiety of
the derivatives, a fragment specific for the respective SCFAs generated most likely from a neutral
loss of isocyanic acid (Table 1; Supplementary Figure S1A–D for the product ion spectra). As a result
of their lower background level, neutral loss fragment ions were used as quantifier. The calculation
of the quantifier/qualifier ion ratios permits the evaluation of specificity for individual samples.
The quantifier/qualifier ratios calculated for a batch with more than 100 different human fecal samples
(data not included here) showed the following variations: FA 2:0 ratio 2.31 (3.4% coefficients of
variation (CV), range 91% to 108% of the mean), FA 3:0 ratio 1.02 (2.8% CV, range 95% to 115% of the
mean), FA 4:0 ratio 0.59 (5.5% CV, range 97% to 110% of mean), and FA 3:0(2Me) ratio 0.40 (4.4% CV,
range 81% to 113% of the mean). Moreover, the mean of these ratios closely resembles those of the
authentic standards and calibrators. For the same study, the variation of the intensities of the internal
standards were calculated as a surrogate for the matrix effects, as follows: [13C,D3]-FA 2:0 (6.2% CV,
range 85% to 118% of the mean), [D5]-FA 3:0 (5.6% CV, range 82% to 113% of the mean), and [D7]-FA
4:0 (3.0% CV, range 92% to 107% of the mean). In addition to the low variation in the IS intensities
between the different samples, the intensities observed in the fecal samples were comparable to those
in the IS blanks and low calibrator levels with diluted sample matrix samples (data not shown).
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3.3. Calibration
Calibration lines were generated in pooled matrix samples, except for the low calibration levels,
which were prepared in a diluted matrix (see Materials and Methods section). These calibrators were
quantified using aqueous standard solutions. The quantification was performed using the respective
matching stable isotope labelled IS. For branched chain FA 3:0(2Me), [D7]-FA 4:0 was utilized as IS,
which showed a retention time in-between both of the C4-isomers (Figure 1). The calibration lines
were linear over a wide range (Supplementary Figure S2A–D).
3.4. Limit of Detection (LoD) and Reproducibility
The frequently determination of the LoD for LC-MS/MS involves a calculation of the signal
to noise (S/N) ratios. Here, S/N could be applied only for FA 4:0 (LoD 0.06 µmol/g DW) and FA
3:0(2Me) (LoD 0.03 µmol/g DW), because the background peaks are virtually absent. However, for FA
2:0 and FA 3:0, the internal standard banks exhibited background signals typically with an S/N of
5 to 7. Therefore, we decided to calculate the LoD for acetate and propionate from the variation
of the internal standard blanks and the variation of a sample with a low concentration (eight-fold
dilution of low QC in Table 2; analysis of five sample aliquots), as described by Armbruster et al. [15]
(Supplementary Table S1). Thus, the LoDs were calculated of 1.9 and 0.20 µmol/g DW for FA 2:0 and
FA 3:0, respectively (Table 1).
Table 2. Precision of SCFA–3NPH quantification. Displayed are within-run (n = 5) and between-run
(n = 6) coefficients of variations (CVs) for fecal samples with low, medium, and high SCFA
concentrations. Mean concentrations are in µmol/g dry weight (DW).
FA 2:0 FA 3:0 FA 4:0 FA 3:0(2Me)
Mean CV Mean CV Mean CV Mean CV
intra-day (n = 5)
low 16 5.1% 4.6 6.1% 4.2 1.9% 1.3 5.1%
medium 203 3.8% 55 2.8% 65 1.3% 12.5 2.3%
high 628 2.6% 141 4.1% 122 2.1% 11.7 1.9%
inter-day (n = 6)
low 16 3.5% 4.5 6.8% 4.1 7.5% 1.4 9.6%
medium 190 5.9% 53 6.5% 62 4.7% 13.8 3.5%
high 561 3.9% 139 4.8% 116 5.8% 12.6 4.8%
The reproducibility of the method was tested in three different human fecal samples, with different
levels of SCFA that were applied as the quality controls (QCs). For all of the QCs, the intra-day variation
was below 6% (Table 2). From day to day, the variations were all below 10%.
Repeated measurement showed that analyte to IS ratio did not changed after two days in a cooled
autosampler (10 ◦C, data not shown). Thus, accurate quantification is also possible after storage of
derivatized samples.
3.5. SCFA Concentrations in Human Feces
The SCFAs were determined in 22 volunteers (Table 3). The mean concentrations of FA 2:0
exceeded those of FA 3:0 and FA 4:0 by about three-fold, while these are about seven-fold higher than
the isobutyric acid concentrations. While the variations observed between the subjects for straight
chain SCFAs were about 60% CV, the isobutyrate level displayed a lower variation with about 40% CV.
Similarly, the span of concentrations were lower than five-fold for FA 3:0 (2Me) compared with more
than 10-fold for the straight SCFAs.
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Table 3. SCFAs concentrations in human feces. Displayed are the SCFAs concentrations determined for
the fecal samples of 22 volunteers.
SCFA (µmol/g DW) Mean± SD Median Min Max
FA 2:0 399 ± 270 341 102 1210
FA 3:0 155 ± 97 121 19 340
FA 4:0 151 ± 95 137 18 370
FA 3:0(2Me) 22 ± 9 19 10 41
3.6. Pre-Analytic Stability in Human Fecal Samples
As microbial activity may continue after defecation, we asked whether the SCFA levels are
altered by sample storage at room temperature or 4 ◦C. Moreover, it was tested if the potential
SCFA metabolism in the fecal samples can be inhibited by the addition of organic solvents.
Therefore, we homogenized the fecal samples of three volunteers within 3 h after defecation,
and prepared aliquots in water, 70% methanol, and 70% isopropanol with identical concentrations.
The aliquots were stored up for to 7 days and the SCFA concentrations were quantified (Figure 2).
Huge differences were observed between the subjects concerning the concentrations and stability of
the individual SCFAs during storage. In the aqueous samples, the SCFA concentrations, especially
those of acetate in subject B, rose about two-fold within six hours. For this sample, the initial FA
2:0 concentration was ~50% higher than in the methanol/isopropanol aliquots. While the SCFA
concentrations typically rise during the storage of aqueous samples, long-term storage for several
days may also result in a significant drop, for example, below 50% of the initial FA 2:0 concentration
after three days for subject C. These changes are substantially lower in the cold. The addition of both
isopropanol and methanol stabilizes the SCFA concentrations even at room temperature.
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3.7. SCFA in the Colon Content of Mice
In a further application of our method, we first asked whether the gut luminal SCFA levels
can be linked with the microbial SCFA producers in the gut (i.e., Bacteroidetes and Firmicutes).
Therefore, the mice were treated for two days with a combination of vancomycin and metronidazole
(VM), before they obtained a regular chow diet without antibiotics for additional 2 or 12 days [5].
We found that the VM treatment significantly decreased the concentrations of all of the analyzed
SCFAs by more than 85% compared with the controls (Figure 3). After the removal of the antibiotics,
the original SCFA levels were restored.
In the second application, we asked if the gut luminal SCFA levels can be associated
with the type of dietary fiber source. The mice were fed either a chow diet containing
grain–soybean-based crude fiber extract (5%), or an experimental control diet with a carbohydrate,
fat, and protein content comparable to chow, but with 5% purified cellulose instead of crude
fiber. Refined cellulose is practically non-degradable and non-fermentable by gut microbiota [16].
As expected, the concentrations of all of the straight chain SCFA levels dropped by more than 50%
in the mice fed the cellulose-containing diet compared with the chow diet (Figure 4). Interestingly,
the isobutyric acid concentration increased almost two-fold in the mice fed a non-degradable and
-fermentable fiber source. However, because of the high variations, only the changes that reached FA
3:0 were of significance.
Biomolecules 2019, 9, 121 9 of 13
Biomolecules 2019, 9, x 9 of 13 
 
Figure 3. SCFA levels in the colon content of SPF mice treated with antibiotics. Specific pathogen-free 
mice were treated for two days with a combination of vancomycin and metronidazole (antibiotics). 
After treatment, the mice obtained a regular chow diet without antibiotics for an additional 2 or 12 
days. The colon content was analyzed at the indicated time points (n = 6 each data point). For three 
samples with antibiotic treatment, the (day 2) FA 4:0 and FA 3:0 (2Me) concentrations were below 
limit of detection LoD; for these samples, two-thirds of the LoD were imputed. 
 
Figure 3. SCFA levels in the colon content of SPF ice treated with antibiotics. Specific pathogen-free
mice were treated for two days with a combination of vancomycin and metronidazole (antibiotics).
After treatment, the mice obtained a regular chow diet without antibiotics for an additional 2 or 12
days. The colon content was analyzed at the indicated time points (n = 6 each data point). For three
samples with antibiotic treatment, the (day 2) FA 4:0 and FA 3:0 (2Me) concentrations were below limit
of detection LoD; for these samples, two-thirds of the LoD were imputed.
Biomolecules 2019, 9, x 9 of 13 
 
Figure 3. SCFA levels in the colon content of SPF mice treated with antibiotics. Specific pathogen-free 
mice were treated for two days with a combination of v ncomycin and metronidazole (antibiotics).
Aft r treatm n , the mice obtained a regular chow diet without a tibiotics for an additio al 2 or 12
days. The colon content was nalyzed at the indicated time points (n = 6 each dat  point). For three
s mples with antibiotic treatment, the (day 2) FA 4:0 and FA 3:0 (2Me) concentr tions were below
li it of detection LoD; fo  thes  samples, two-thirds of the LoD were imputed. 
 
Figure 4. SCFA levels in the colon content of the SPF mice fed a diet containing a non-degradable
and -fermentable fiber source. Specific pathogen-free mice were fed for two weeks either a chow diet
containing a grain–soybean-based crude fiber extract (5%), or an experimental control diet with 5%
purified cellulose instead of crude fiber. The SCFA concentrations were analyzed in the colon content
(n = 6 each group); ** p < 0.01.
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4. Discussion
Here, we present a fast and reproducible method for the quantification of SCFAs for up to four
carbon atoms using the LC-MS/MS of 3NPH-dervatives. It is well known that accurate quantification
requires the use of IS, preferably of the stable isotope labelled analyte [17]. Some methods apply
labelled derivatization agents, like 13C-aniline [11] or 13C6-3NPH [9], to generate labelled SCFA
derivatives. Typically, the labelled SCFA derivatives were spiked to derivatized the samples as
IS [9]. Chan et al. used labelled SCFA derivatives to generate calibration lines. A drawback of
such methods is that the derivatization efficiency of the individual sample could not be monitored.
Here, stable isotope labelled SCFAs were added prior to the derivatization in order to control the
entire sample preparation. Highly-labelled SCFAs were utilized to prevent the isotopic overlap of
analyte and IS. Moreover, their high mass shift also permits application in tracer experiments using
13C-labeling (e.g., to trace the synthesis of fatty acids from acetate) [5,18,19].
Similar signal intensities of IS in the samples with and without a matrix, as well as low signal
variations between the different samples, provide substantial evidence that the matrix effects are low in
the present method. The specificity of the method could be demonstrated by the calculation of the ratios
of the quantifier and qualifier ions. The determination of LoD for FA 2:0 and 3:0 needs consideration
for their significant background levels. A similar background could also be observed for main long
chain fatty acids like FA 16:0 and 18:0 [20]. However, the SCFA levels observed for both the human
and mouse studies are significantly above the LoDs of the present method. The high reproducibility,
at a broad range of SCFA concentrations, and the short run time of only 4 min, make this method a
valuable tool for large scale studies.
The SCFA concentrations were normalized here to the DW determined in an aliquot of the
homogenized sample. It is well known that the water content of the feces may vary substantially
(normal stool about 75%), especially when diarrheic samples (>85%) are included [21,22]. As we also
aim for the application of this method in a disease-related context, the dilution effects need to be
addressed, as shown for the application of fecal elastase in patient diagnosis [22]. Therefore, samples
were adjusted to 2mg DW/mL, similar to that described for the sterol/stanol quantification [12]. As the
reported SCFA concentrations in the literature are largely related to the wet weight, we multiplied
these concentrations by four to get a concentration related to the DW. This factor is based on normal
stools with a mean water content of 75% [21], or on data showing a median fecal wet mass production
of 128 g/cap/day, with a median dry mass of 29 g/cap/day [23]. So, we recalculated the mean SCFA
concentrations of the human fecal samples reported in previous studies to µmol/g DW, as follows:
Han et al. [9], 6 subjects determined by LC-MS/MS (FA 2:0—138, FA 3:0—38, FA 4:0—12, FA 3:0
(2Me)—25); Hoverstad et al. [24], 20 subjects determined by vacuum distillation and subsequent gas
chromatography (FA 2:0—150, FA 3:0—50, FA 4:0—50, FA 3:0 (2Me)—9); Gardana et al. [25], 40 subjects
determined by LC-HRMS (FA 2:0—170, FA 3:0—68, FA 4:0—48, FA 3:0(2Me)—8); and Garcia-Villalba
et al. [26], 8 subjects determined by GC-MS (FA 2:0—127, FA 3:0—28, FA 4:0—28, FA 3:0(2Me)—6).
The mean concentrations observed here, were about two- to three-fold higher, which may either be
related to the analyzed sample collective and/or to a bias introduced by assumption of the water
content. The ratio of SCFA concentrations typically about 3:1:1:0.15 for FA 2:0/FA 3:0/FA 4:0/FA
3:0(2Me) determined in most of the previous studies fits to our data and to SCFA level detected in the
large intestine [27].
To achieve accurate concentrations, pre-analytic stability of analytes needs to be evaluated [28].
This is of special importance for metabolically highly active specimen like fecal samples [29]. Gratton
et al. investigated the fecal metabolome using 1H NMR spectroscopy, and recommended the
transportation of samples on ice [30], because an increase in the SCFA concentrations was observed
within a few hours at room temperature. Interestingly, the freezing of samples and their subsequent
storage at room temperature resulted in decreased SCFA concentrations. Here, we evaluated the
storage effects in three different subjects, and realized huge differences between the subjects concerning
the changes during storage. Changes were smaller at lower temperatures and could be prevented
Biomolecules 2019, 9, 121 11 of 13
by the addition of organic solvents like methanol or isopropanol. These data confirm the data of
Torii et al., demonstrating that addition of 70% ethanol stabilizes fecal SCFA concentrations at room
temperature [31]. As the methanol and isopropanol did not show significant differences in stabilizing
the concentrations of SCFA, we prefer the addition of isopropanol directly upon the collection of stool
samples. Furthermore, the addition of isopropanol to the fecal samples decreased the microbiological
hazards to the laboratory staff dealing with the analysis of those samples.
Finally, the method was applied to investigate the colon content of the mice collected in a previous
study investigating the effect of intestinal microbial colonization on hepatic lipid metabolism [5].
The high variation of the SCFA level between the mice may be related to the variability in the
amount and distribution of the colon content. Both treatment with antibiotics and dietary intervention
with a non-degradable and -fermentable fiber source resulted, as expected, in a decrease of SCFA
concentrations. The finding that the isobutyric acid levels were dropped only when the mice were
treated with antibiotics, but not in the cellulose-containing dietary intervention, can be explained by
its generation from branched-chain amino acids, but not dietary fiber [6].
5. Conclusions
In conclusion, the presented method provides a fast and robust quantification of fecal SCFA
concentrations, which represent a useful tool for both basic research and large-scale studies. Besides
its short run time, the main advances compared to previous methods are the application of
quantifier/qualifier ions and the matching stable isotope labelled internal standards. Moreover, it was
demonstrated that the fecal SCFA level may change rapidly in aqueous samples, and the addition of
organic solvents like isopropanol stops SCFA metabolism.
Supplementary Materials: The following are available online. Figure S1A–D: Product ion spectra of SCFA-3NPH
derivatives; Figure S2A–D: Calibration lines; Table S1: LoD determination.
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